During the past decade, Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 4 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 1 clinical trials were completed. i.e. 6.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica" #1 sponsor was "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 10 trials, followed by "Gruppo Italiano Trapianto di Midollo Osseo" with 7 trials sponsored, "Fondazione Italiana Linfomi ONLUS" with 6 trials sponsored, "Hoffmann-La Roche" with 5 trials sponsored and "Fondazione Italiana Sindromi Mielodisplastiche-ETS" with 5 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica" #1 collaborator was "Associazione Italiana di Immunogenetica e Biologia dei Trapianti (AIBT)" with 1 trials as a collaborator, "Azienda Policlinico Umberto I" with 1 trials as a collaborator, "Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte" with 1 trials as a collaborator, "ERIC Group" with 1 trials as a collaborator and "German Low Grade Lymphoma Study Group" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica" are "Acute Myeloid Leukemia" (5 trials), "Myelofibrosis" (3 trials), "Follicular Lymphoma" (2 trials), "Hematologic Diseases" (2 trials) and "Mantle Cell Lymphoma" (2 trials). Many other conditions were trialed in "Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica" in a lesser frequency.

Most popular intervention types in "Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica" are "Drug" (22 trials), "Other" (4 trials), "Combination Product" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Rituximab" (3 trials), "Glasdegib" (2 trials), "Obinutuzumab" (2 trials), "rituximab [MabThera/Rituxan]" (2 trials) and "A: Fludarabine + Busulphan" (1 trials). Other intervention names were less common.

The vast majority of trials in "Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica" are 32 trials for "All" genders.

Currently, there are NaN active trials in "Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica". 1 are not yet recruiting, 10 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica, 1 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".